Hylomorph

Hylomorph is an innovative Medtech company based in Switzerland, founded in 2014. The company aims to prevent post-operative complications in implantable medical devices by engineering biomaterials to optimize the interface between implants and surrounding biological tissues. With the mission to improve the quality of life for patients and the care provided by health professionals, Hylomorph has developed proprietary CellSense technology in collaboration with the cutting-edge laboratories of the Swiss Federal Institute of Technology (ETH Zurich).

The company's first product, Hylomate, has shown remarkable performance in limiting foreign body reaction and fibrotic buildup in pre-clinical settings. Currently, it is undergoing first-in-man clinical trials in Germany. Hylomorph has recently secured a significant Fr.4.50M Series B investment led by a consortium of investors including Verve Ventures, EFI Lake Geneva Ventures, Excellis, The Investors Club, Interconsult, StartAngels Network, and Zürcher Kantonal Bank on 05 September 2023.